(Q53621974)

English

A Phase I Pharmacokinetic Study of Trastuzumab Emtansine (T-DM1) in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/27995530

A Phase I Pharmacokinetic Study of Trastuzumab Emtansine (T-DM1) in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function. (English)

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/27995530

metastatic breast cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Chunze Li

1

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/27995530

Priya Agarwal

2

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/27995530

Ekaterina Gibiansky

3

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/27995530

Jin Yan Jin

4

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/27995530

Susan Dent

5

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/27995530

Anthony Gonçalves

6

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/27995530

Ihsan Nijem

7

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/27995530

Alexander Strasak

8

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/27995530

Marie-Laurence Harle-Yge

9

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/27995530

Nataliya Chernyukhin

10

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/27995530

Pat LoRusso

11

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/27995530

Sandhya Girish

12

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/27995530

publication date

1 September 2017

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/27995530

Clinical Pharmacokinetics

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/27995530

56

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/27995530

9

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/27995530

1069-1080

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/27995530

https://scigraph.springernature.com/pub.10.1007/s40262-016-0496-y

0 references

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0496-Y

21 January 2018

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0496-Y

21 January 2018

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0496-Y

21 January 2018

Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0496-Y

21 January 2018

Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0496-Y

21 January 2018

Causes of death in breast cancer: a clinicopathologic study

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0496-Y

21 January 2018

PK assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0496-Y

21 January 2018

Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0496-Y

21 January 2018

Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0496-Y

21 January 2018

Clinical pharmacokinetics of bevacizumab in patients with solid tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0496-Y

21 January 2018

Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0496-Y

21 January 2018

Identification of amino acid residues responsible for the release of free drug from an antibody-drug conjugate utilizing lysine-succinimidyl ester chemistry

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0496-Y

21 January 2018

Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27995530

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro characterization of the drug-drug interaction potential of catabolites of antibody-maytansinoid conjugates

1 reference

https://pubmed.ncbi.nlm.nih.gov/27995530

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Liver metastases from breast cancer: the relationship between clinical, biochemical and pathological features and survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/27995530

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40262-016-0496-Y

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/27995530

1 reference

Europe PubMed Central

16 May 2018

http://europepmc.org/abstract/MED/27995530

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53621974&oldid=1992728878"